Pharma & Biotech Global Week in Review 22 September 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Tarceva (Erlotinib) – India: Matrix restrained from infringing Roche’s patent (Spicy IP)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

New IP resource for pharma, biotech and chem and you can’t always get what you want – restrictions on remedies in IP litigation (IP Think Tank)

How nuts! – Peanut based malnutrition treatment – humanitarian developments and compulsory licensing (IP finance)

NGOs warn on IP in Trans Pacific Trade Agreement (IP Watch)

Africa: African traditional knowledge and folklore given IP protection despite warning of TK commodification (IP Watch)

Brazil, EU, India, Netherlands: Consultations on WTO drug transit case continue (IP Watch)

EU: Vaccines causing trouble once more… Georgetown University referral to ECJ concerning SPC Regulation (The SPC Blog) (IPKat)

India: Health Ministry set to resolve patent linkage question for drug marketing approval once and for all (Spicy IP) (GenericsWeb)

India: New decisions from the Patent Office: Roche v Cipla, Nycomed application no 1169/MUMNP/2006, IPCA application no 416/MUMNP/2007, Cipla v Cadila  (Indian Patent Oppositions)

Sweden: New Swedish PRV search includes SPCs (The SPC Blog)

US: Prometheus v Mayo: Patenting medical methods (Patently-O)

US: Are the wild west days of DNA sequence patenting over?: AMP et al v USPTO et al; Intervet v Merial (ipeg)

US: OGD has put the brakes on ANDA supplement reviews; Will it help push generic drug user fees along? (FDA Law Blog)

US: FDA set to announce public hearing on BPCI Act implementation (FDA Law Blog)

US: Precision Biosciences granted stay pending reexam of Cellectis’ patents (Patent Docs)

US: Celsis granted preliminary injunction against CellzDirect in LiverPool hepatocyte treatment infringement suit (Patent Docs)

US: Yeda Research and Development files suit against Abbott in District of Columbia requesting review of BPAI decision (Patent Docs)

Products

Angiomax (Bivalirudin) – US: The Medicines Company clearing last hurdles to patent term extension for Angiomax (Patent Docs)

Copaxone (Glatiramer) – US: Sandoz, Momenta fail to invalidate Teva patents in Copaxone suit (Patent Docs)

Norvir (Ritonavir) – EU: General Court annuls decision of OHIM BoA that no likelihood of confusion existed between marks SORVIR and NORVIR for pharmaceutical products (Class 46)

Seroquel (Quetiapine) – US: AstraZeneca files patent infringement suit against Osmotica in response to Para IV certification (Patent Docs)

Tarceva (Erlotinib) – India: Matrix restrained from infringing Roche’s patent (Spicy IP)

Temodar (Temozolomide) – US: Cancer Research Technology, Schering Corp file patent infringement suit against Sun following Para IV challenge (Patent Docs)

Zinacef (Cefuroxime) – Kenya: Court of Appeal allows continued sale of drugs pending appeal in trade mark dispute concerning ‘Synercef’: Syner-Med Pharmaceuticals Ltd v Glaxo Group Limited (Afro-IP)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: